The company will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors. The therapy is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback